

Supporting Information for:

Synthesis of fluorescent ring-fused 2-pyridone peptidomimetics

K. Syam Krishnan,¹ Christoffer Bengtsson,¹ James A. D. Good,¹ Shamil Mirkhanov,¹ Erik Chorell,¹ Lennart B. –Å. Johansson,¹ Fredrik Almqvist.*^{1,2}

¹ Umeå University, Department of Chemistry, 901 87 Umeå, Sweden; ² Umeå Centre for Microbial Research, Umeå University, 901 87 Umeå, Sweden.

* Corresponding author: Prof. Fredrik Almqvist, Department of Chemistry, Umeå University SE-90187 Umeå, Sweden; Fax: (+46)907867655; Email: fredrik.almqvist@chem.umu.se

Table of Contents:

Figure S1 – Time-resolved fluorescence decay of 19c	S3
Scheme S1 – Original route towards BODIPY-containing thiazolino 2-pyridones	S4
Scheme S2 – Revised route towards BODIPY-containing thiazolino 2-pyridones	S4
Table S1 - Screened hydrolysis conditions for BODIPY methyl ester 17a	S5
Table S2: LiI halogenolysis of BODIPY methyl esters	S6
<i>NMR Spectra:</i>	
Compound 10 , ¹ H NMR and ¹³ C NMR	S7
Compound 12 , ¹ H NMR and ¹³ C NMR	S8
Compound 13 , ¹ H NMR and ¹³ C NMR	S9
Compound 8 , ¹ H NMR and ¹³ C NMR	S10
Compound 14a , ¹ H NMR and ¹³ C NMR	S11
Compound 14b , ¹ H NMR and ¹³ C NMR	S12
Compound 14c , ¹ H NMR and ¹³ C NMR	S13
Compound 15 , ¹ H NMR and ¹³ C NMR	S14
Compound 16 , ¹ H NMR and ¹³ C NMR	S15
Compound 6 , ¹ H NMR and ¹³ C NMR	S16
Compound 17a , ¹ H NMR and ¹³ C NMR	S17
Compound 17b , ¹ H NMR and ¹³ C NMR	S18
Compound 17c , ¹ H NMR and ¹³ C NMR	S19
Compound 18 , ¹ H NMR and ¹³ C NMR	S20
Compound 19a , ¹ H NMR and ¹³ C NMR	S21
Compound 19b , ¹ H NMR and ¹³ C NMR	S22
Compound 19c , ¹ H NMR and ¹³ C NMR	S23
Supplementary References	S24





FIGURE S1 - Time-resolved fluorescence decay of **19c** dissolved in DMSO at 25 °C [$F(t)$, *i.e.* the number of counted photons *vs.* time]. In the lower graph, the upper curve reveals biphasic fluorescence decay, while the lower curve displays the instrumental response function. The upper graph shows the weighted residual obtained by fitting the decay to a sum of exponential functions.

SCHEME S1 – Original route towards BODIPY containing thiazolino 2-pyridones.¹



SCHEME S2 – Revised route towards BODIPY-containing thiazolino 2-pyridones.




TABLE S1 - Screened hydrolysis conditions for BODIPY methyl ester **17a**.


Entry	Hydrolysis method	Solvent	Temp (°C)	Time	LCMS conversion (isolated yield)	Notes/Reference
1	LiOH	THF/MeOH	rt	2 h	-	¹
2	LiOH	Dioxane	rt	16 h	-	
3	NaOH	THF/MeOH	rt	30 min	-	Decomposition. ²
4	KOH	THF/MeOH	rt	30 min	-	Decomposition. ³
5	K ₂ CO ₃	DMF	rt	6 h	-	
6	TMSI	CCl ₄ /CDCl ₃	rt	6 h	-	⁴
7	TMSI, MWI	CCl ₄ /CDCl ₃	60-90	20 min	-	⁴
8	Me ₃ SnOH	DCE	rt	6 h	-	⁵
9	Me ₃ SnOH, MWI	DCE	80-110	30 min	-	⁵
10	<i>Mucor javanicus</i>	Acetone /phosphate buffer	38	6 h	-	
11	<i>Candida antarctica</i> lipase B	THF/phosphate buffer	38	6 h	-	
12	Et ₃ N (20 eq.), LiBr (20 eq.)	MeCN/H ₂ O (98/2)	rt	24 h	<16%	⁶
13	Et ₃ N (20 eq.), LiBr (20 eq.)	THF/H ₂ O (98/2)	rt	24 h	-	⁶
14	Et ₃ N (20 eq.), LiBr (20 eq.)	MeOH/H ₂ O (98/2)	rt	24 h	-	⁶
15	Et ₃ N (20 eq.), KBr (20 eq.)	MeCN/H ₂ O (98/2)	rt	24 h	-	
16	Et ₃ N (20 eq.), LiBr (20 eq.)	MeCN/H ₂ O (98/2)	40	5 h	16%	Complex mixture of products. ⁶
17	DABCO (20 eq.), LiBr (20 eq.)	MeCN/H ₂ O (98/2)	40	5 h	-	⁶
18	DBU (20 eq.), LiBr (20 eq.)	MeCN/H ₂ O (98/2)	40	5 h	-	Decomposition. ⁶
19	DMAP (20 eq.), LiBr (20 eq.)	MeCN/H ₂ O (98/2)	40	5 h	-	⁶
20	LiCl (15 eq.), MWI	DMF	80	15 min	-	⁷
21	LiBr (15 eq.), MWI	DMF	80	15 min	Trace	
22	LiBr (15 eq.)	DMF	rt	16 h	-	
23	LiBr (15 eq.)	DMF	60	4 h	-	
24	LiBr (10 eq.), MWI	DMF	90	2 h	16%	
25	LiBr (10 eq.), MWI	DMF/H ₂ O (90/10)	90	2 h	20%	
26	LiBr (50 eq.), MWI	DMF	90	70 min	75% (65%)	

TABLE S2 - LiI halogenolysis in DMF of BODIPY methyl esters.


Compound	Structure	Conditions	Conversion	Lit. Yield	Lit. Conditions
S4		MWI, 110 °C, 30 min	70% ^a	88%	(i) 0.1 M LiOH (aq), THF/MeOH (4:1) 2 h; (ii) AcOH. ¹
S5		MWI, 140 °C, 10 min	Trace	29% ^b	(i) LiI, pyridine, MWI, 140 °C, 15 min; (ii) BF ₃ ·Et ₂ O, DCE, 80 °C, 15 min. ¹
6		MWI, 140 °C, 12 min	100% ^a	n/a	-
S6		MWI, 100 °C, 1 h	40% ^a	n/a	-
S7		MWI, 120 °C, 1 h	50% ^a	n/a	-
S8		MWI, 110 °C, 20 min	80% ^a	88%	(i) LiBr, NEt ₃ , MeCN (2 v/v% H ₂ O), 3h (ii) AcOH. ¹

Notes: a = LC-MS conversion; b = removal of BF₂ observed. n/a = not available.


^1H NMR spectra of **10** (CDCl_3)




^{13}C NMR spectra of **10** (CDCl_3)




^1H NMR spectra of **12** (CDCl_3)




^{13}C NMR spectra of **12** (CDCl_3)




^1H NMR spectra of **13** (MeOD + CDCl_3)




^{13}C NMR spectra of **13** (MeOD + CDCl_3)




^1H NMR spectra of **8** (MeOD)




^{13}C NMR spectra of **8** (MeOD)




^1H NMR spectra of **14a** (MeOD)




^{13}C NMR spectra of **14a** (MeOD)




^1H NMR spectra of **24b** (MeOD + CDCl_3)




^{13}C NMR spectra of **14b** (MeOD + CDCl_3)




^1H NMR spectra of **14c** (CDCl_3)




^{13}C NMR spectra of **14c** (CDCl_3)




^1H NMR spectra of **15** (MeOD + CDCl_3)




^{13}C NMR spectra of **15** (MeOD + CDCl_3)




^1H NMR spectra of **16** (MeOD + CDCl_3)




^{13}C NMR spectra of **16** (MeOD + CDCl_3)




^1H NMR spectra of **6** (CDCl_3)




^{13}C NMR spectra of **6** (CDCl_3)




^1H NMR spectra of **17a** (CDCl_3)




^{13}C NMR spectra of **17a** (CDCl_3)




^1H NMR spectra of **17b** (CDCl_3)




^{13}C NMR spectra of **17b** (CDCl_3)




^1H NMR spectra of **17c** (CDCl_3)




^{13}C NMR spectra of **17c** (CDCl_3)





^1H NMR spectra of **18** (DMSO- d_6)




^{13}C NMR spectra of **18** (DMSO- D_6)







^1H NMR spectra of **19b** (MeOD + CDCl_3)




^{13}C NMR spectra of **19b** (MeOD + CDCl_3)



^1H NMR spectra of **19c** (CDCl_3)



^{13}C NMR spectra of **19c** (CDCl_3)



Supplementary References

- (1) Chorell, E.; Pinkner, J. S.; Bengtsson, C.; Edvinsson, S.; Cusumano, C. K.; Rosenbaum, E.; Johansson, L. B. Å.; Hultgren, S. J.; Almqvist, F. *Chem. Eur. J.* **2012**, *18*, 4522.
- (2) Boldyrev, I. A.; Zhai, X.; Momsen, M. M.; Brockman, H. L.; Brown, R. E.; Molotkovsky, J. G. *J. Lipid Res.* **2007**, *48*, 1518.
- (3) Komatsu, T.; Urano, Y.; Fujikawa, Y.; Kobayashi, T.; Kojima, H.; Terai, T.; Hanaoka, K.; Nagano, T. *Chem. Commun.* **2009**, 7015.
- (4) Jung, M. F.; Lyster, M. A. *J. Am. Chem. Soc.* **1977**, *99*, 968.
- (5) Nicolaou, K. C.; Estrada, A. A.; Zak, M.; Lee, S. H.; Safina, B. S. *Angew. Chem. Int. Ed.* **2005**, *44*, 1378.
- (6) Mattsson, S.; Dahlström, M.; Karlsson, S. *Tetrahedron Lett.* **2007**, *48*, 2497.
- (7) Wu, X.-A.; Ying, P.; Liu, J.-Y.; Shen, H.-S.; Chen, Y.; He, L. *Synth. Commun.* **2009**, *39*, 3459.